Details
Stereochemistry | RACEMIC |
Molecular Formula | C8H18NO2 |
Molecular Weight | 160.234 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 1 |
SHOW SMILES / InChI
SMILES
CC(C[N+](C)(C)C)OC(C)=O
InChI
InChIKey=NZWOPGCLSHLLPA-UHFFFAOYSA-N
InChI=1S/C8H18NO2/c1-7(11-8(2)10)6-9(3,4)5/h7H,6H2,1-5H3/q+1
Molecular Formula | C8H18NO2 |
Molecular Weight | 160.234 |
Charge | 1 |
Count |
|
Stereochemistry | MIXED |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/17565027Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019193s013lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/9622546
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17565027
Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019193s013lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/9622546
Methacholine (trade name Provocholine) is a synthetic choline ester that acts as a muscarinic receptor agonist. Methacholine is primarily used to diagnose bronchial hyperreactivity, which is the hallmark of asthma and also occurs in chronic obstructive pulmonary disease. This is accomplished through the bronchial challenge test, or methacholine challenge, in which a subject inhales aerosolized methacholine, leading to bronchoconstriction.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL245 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9622546 |
|||
Target ID: CHEMBL211 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9622546 |
59.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | PROVOCHOLINE Approved UseProvocholine® (methacholine chloride powder for inhalation) is indicated for the diagnosis of bronchial airway hyperreactivity in subjects who do not have clinically apparent asthma. Launch Date5.31100795E11 |
Doses
Dose | Population | Adverse events |
---|---|---|
16 mg/mL 5 times / day multiple, respiratory (max) Recommended Dose: 16 mg/mL, 5 times / day Route: respiratory Route: multiple Dose: 16 mg/mL, 5 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Bronchial airway hyperreactivity Sources: Page: p.1 |
Disc. AE: Bronchoconstriction... AEs leading to discontinuation/dose reduction: Bronchoconstriction (severe) Sources: Page: p.1 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Bronchoconstriction | severe Disc. AE |
16 mg/mL 5 times / day multiple, respiratory (max) Recommended Dose: 16 mg/mL, 5 times / day Route: respiratory Route: multiple Dose: 16 mg/mL, 5 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Bronchial airway hyperreactivity Sources: Page: p.1 |
PubMed
Title | Date | PubMed |
---|---|---|
The effect of acute alteration in oxygen tension on the bronchodilator response to salbutamol in vitro and in vivo in man. | 2001 |
|
Airway foreign body with clinical features mimicking bronchial asthma. | 2001 |
|
Bronchial hyperresponsiveness and exhaled nitric oxide in patients with cardiac disease. | 2001 |
|
Clinical and immunologic changes after allergen immunotherapy with Hop Japanese pollen. | 2001 Apr |
|
Glucocorticoid treatment increases inhibitory m(2) muscarinic receptor expression and function in the airways. | 2001 Apr |
|
Gibbs sampling-based segregation analysis of asthma-associated quantitative traits in a population-based sample of nuclear families. | 2001 Apr |
|
Effects of smooth muscle activation on axial mechanical properties of excised canine bronchi. | 2001 Apr |
|
G(q/11) and G(i/o) activation profiles in CHO cells expressing human muscarinic acetylcholine receptors: dependence on agonist as well as receptor-subtype. | 2001 Feb |
|
The lack of the bronchoprotective and not the bronchodilatory ability of deep inspiration is associated with airway hyperresponsiveness. | 2001 Feb |
|
Oilseed rape flour: another allergen causing occupational asthma among farmers. | 2001 Feb |
|
Chronic tobacco smoke exposure increases airway sensitivity to capsaicin in awake guinea pigs. | 2001 Feb |
|
Abnormal responses to endothelial agonists in Raynaud's phenomenon and scleroderma. | 2001 Jan |
|
Effect of cetirizine on bronchial hyperresponsiveness in patients with seasonal allergic rhinitis and asthma. | 2001 Jan |
|
Pulmonary function response to EDTA, an additive in nebulized bronchodilators. | 2001 Jan |
|
Relaxant effect of Pimpinella anisum on isolated guinea pig tracheal chains and its possible mechanism(s). | 2001 Jan |
|
Enhancement of goblet cell hyperplasia and airway hyperresponsiveness by salbutamol in a rat model of atopic asthma. | 2001 Jan |
|
Hydrocortisone abolishes the angiotensin II-mediated potentiation of endothelin-1 in bovine bronchi. | 2001 Jan |
|
[Asthma related to inhalation of Plantago ovata]. | 2001 Jan 13 |
|
Developmental expression of neurokinin A and functional neurokinin-2 receptors in lung. | 2001 Jun |
|
SCF-induced airway hyperreactivity is dependent on leukotriene production. | 2001 Jun |
|
Possible involvement of Rho kinase in Ca2+ sensitization and mobilization by MCh in tracheal smooth muscle. | 2001 Jun |
|
Regulation of secretion from mucous and serous cells in the excised ferret trachea. | 2001 Jun |
|
Chronic tobacco smoke exposure increases cough to capsaicin in awake guinea pigs. | 2001 Jun |
|
Airway responses to a diluent used in the methacholine challenge test. | 2001 Mar |
|
The transcription factor early growth-response factor 1 modulates tumor necrosis factor-alpha, immunoglobulin E, and airway responsiveness in mice. | 2001 Mar |
|
Temporal association between airway hyperresponsiveness and airway eosinophilia in ovalbumin-sensitized mice. | 2001 Mar |
|
Drug treatment of airway inflammation in asthma. | 2001 Mar |
|
Methacholine challenge testing in Reserve Officer Training Corps cadets. | 2001 Mar |
|
Tidal midexpiratory flow as a measure of airway hyperresponsiveness in allergic mice. | 2001 Mar |
|
Polycystic ovary syndrome is associated with endothelial dysfunction. | 2001 Mar 13 |
|
Role of K+ channels in N-acetylprocainamide-induced relaxation of bovine tracheal smooth muscle. | 2001 Mar 9 |
|
Muscarinic depression of synaptic transmission in the epileptogenic GABA withdrawal syndrome focus. | 2001 May |
|
Airway inflammation and bronchial hyperresponsiveness after Mycoplasma pneumoniae infection in a murine model. | 2001 May |
|
Occupational asthma caused by exposure to cyanoacrylate. | 2001 May |
|
Validation of a new questionnaire on asthma, allergic rhinitis, and conjunctivitis in young adults. | 2001 May |
|
Dose-response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled beclomethasone dipropionate therapy in asthma patients. | 2001 May |
|
Eosinophil markers in blood, serum, and urine for monitoring the clinical course in childhood asthma: impact of budesonide treatment and withdrawal. | 2001 May |
Patents
Sample Use Guides
Provocholine is inhaled using a standardized procedure. The challenge is performed by giving a subject ascending serial concentrations of Provocholine. At each concentration, five breaths are administered by a nebulizer that permits intermittent delivery time of 0.6 seconds by a breath-actuated timing device (dosimeter). At each of five inhalations of a serial concentration, the subject begins at functional residual capacity (FRC) and slowly and completely inhales the dose delivered. Within 5 minutes, FEV1 values are determined. The procedure ends either when there is a 20% or greater reduction in the FEV1 compared with the baseline sodium chloride solution value (i.e., a positive response) or if 188.88 total cumulative units have been administered and the FEV1 has been reduced by 14 % or less (i.e., a negative response). If there is a reduction of 15% to 19% in the FEV, compared with baseline, either the challenge may be repeated at that concentration or a higher concentration may be given as long as the dosage administered does not result in total cumulative units exceeding 188.88.
Route of Administration:
Respiratory
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9622546
Agonist activity of methacholine was determined using assay of accumulation of [3H]inositol monophosphate. The CHO cells were labeled in 12-well plates with 1 uCi/mL myo-[3H]inositol for 24 h. Wells contained ca. 3* 10^5 cells in a volume of 1 mL. Cells were then washed once with Hank’s balanced salt media containing 20 mM HEPES buffer (pH 7.4) and were then incubated in the buffered Hank’s media containing 10 mM LiCl at room temperature for 15 min. Muscarinic agents were then added to each well. After incubation for 1 h at 37 °C, the medium was aspirated and replaced with 750 uL of cold 20 mM aqueous formic acid. After 35 min at 4 °C, the formic acid was removed and replaced with 250 uL of 60 mM NH4OH. The inositol monophosphate in the NH4OH solution was isolated by anionexchange chromatography19 and counted for tritium in Hydrofluor scintillation fluid. Cells were treated with 0.001 - 10 uM of methacholine, EC50 was determined to be 120 nM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 18:35:24 UTC 2022
by
admin
on
Fri Dec 16 18:35:24 UTC 2022
|
Record UNII |
03V657ZD3V
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175369
Created by
admin on Fri Dec 16 18:35:24 UTC 2022 , Edited by admin on Fri Dec 16 18:35:24 UTC 2022
|
||
|
NCI_THESAURUS |
C1937
Created by
admin on Fri Dec 16 18:35:24 UTC 2022 , Edited by admin on Fri Dec 16 18:35:24 UTC 2022
|
||
|
NDF-RT |
N0000175884
Created by
admin on Fri Dec 16 18:35:24 UTC 2022 , Edited by admin on Fri Dec 16 18:35:24 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
7438
Created by
admin on Fri Dec 16 18:35:24 UTC 2022 , Edited by admin on Fri Dec 16 18:35:24 UTC 2022
|
PRIMARY | |||
|
03V657ZD3V
Created by
admin on Fri Dec 16 18:35:24 UTC 2022 , Edited by admin on Fri Dec 16 18:35:24 UTC 2022
|
PRIMARY | |||
|
METHACHOLINE
Created by
admin on Fri Dec 16 18:35:24 UTC 2022 , Edited by admin on Fri Dec 16 18:35:24 UTC 2022
|
PRIMARY | |||
|
155080
Created by
admin on Fri Dec 16 18:35:24 UTC 2022 , Edited by admin on Fri Dec 16 18:35:24 UTC 2022
|
PRIMARY | RxNorm | ||
|
DTXSID2046967
Created by
admin on Fri Dec 16 18:35:24 UTC 2022 , Edited by admin on Fri Dec 16 18:35:24 UTC 2022
|
PRIMARY | |||
|
55-92-5
Created by
admin on Fri Dec 16 18:35:24 UTC 2022 , Edited by admin on Fri Dec 16 18:35:24 UTC 2022
|
PRIMARY | |||
|
DB06709
Created by
admin on Fri Dec 16 18:35:24 UTC 2022 , Edited by admin on Fri Dec 16 18:35:24 UTC 2022
|
PRIMARY | |||
|
C61837
Created by
admin on Fri Dec 16 18:35:24 UTC 2022 , Edited by admin on Fri Dec 16 18:35:24 UTC 2022
|
PRIMARY | |||
|
03V657ZD3V
Created by
admin on Fri Dec 16 18:35:24 UTC 2022 , Edited by admin on Fri Dec 16 18:35:24 UTC 2022
|
PRIMARY | |||
|
6804
Created by
admin on Fri Dec 16 18:35:24 UTC 2022 , Edited by admin on Fri Dec 16 18:35:24 UTC 2022
|
PRIMARY | |||
|
SUB03201MIG
Created by
admin on Fri Dec 16 18:35:24 UTC 2022 , Edited by admin on Fri Dec 16 18:35:24 UTC 2022
|
PRIMARY | |||
|
1726
Created by
admin on Fri Dec 16 18:35:24 UTC 2022 , Edited by admin on Fri Dec 16 18:35:24 UTC 2022
|
PRIMARY | |||
|
1993
Created by
admin on Fri Dec 16 18:35:24 UTC 2022 , Edited by admin on Fri Dec 16 18:35:24 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |